[1] Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, Scheltens P, Tariska P, Winblad B (2007) Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 14, e1-26.
[2] Segal-Gidan F, Cherry D, Jones R, Williams B, Hewett L, Chodosh J (2011) Alzheimer's disease management guideline: update 2008. Alzheimers Dement 7, e51-59.
[3] Hort J, O'Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, Sorbi S, Scheltens P (2010) EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 17, 1236-1248.
[4] Blanco-Silvente L, Castells X, Saez M, Barcelo MA, Garre-Olmo J, Vilalta-Franch J, Capella D (2017) Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer's Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients. Int J Neuropsychopharmacol 20, 519-528.
[5] Cummings J, Lee G, Ritter A, Zhong K (2018) Alzheimer's disease drug development pipeline: 2018. Alzheimers Dement (N Y) 4, 195-214.
[6] Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K (2019) Alzheimer's disease drug development pipeline: 2019. Alzheimers Dement (N Y) 5, 272-293.
[7] Amanatkar HR, Papagiannopoulos B, Grossberg GT (2017) Analysis of recent failures of disease modifying therapies in Alzheimer's disease suggesting a new methodology for future studies. Expert Rev Neurother 17, 7-16.
[8] Cao J, Hou J, Ping J, Cai D (2018) Advances in developing novel therapeutic strategies for Alzheimer's disease. Mol Neurodegener 13, 64.
[9] Mehta D, Jackson R, Paul G, Shi J, Sabbagh M (2017) Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015. Expert Opin Investig Drugs 26, 735-739.
[10] Gold M (2007) Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease. J Clin Psychiatry 68, 430-438.
[11] Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T (2010) Disease progression meta-analysis model in Alzheimer's disease. Alzheimers Dement 6, 39-53.
[12] Wattmo C (2013) Prediction models for assessing long-term outcome in Alzheimer's disease: a review. Am J Alzheimers Dis Other Demen 28, 440-449.
[13] Ito K, Corrigan B, Zhao Q, French J, Miller R, Soares H, Katz E, Nicholas T, Billing B, Anziano R, Fullerton T (2011) Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database. Alzheimers Dement 7, 151-160.
[14] Ito K, Hutmacher MM, Corrigan BW (2012) Modeling of Functional Assessment Questionnaire (FAQ) as continuous bounded data from the ADNI database. J Pharmacokinet Pharmacodyn 39, 601-618.
[15] Qiu Y, Li L, Zhou TY, Lu W (2014) Alzheimer's disease progression model based on integrated biomarkers and clinical measures. Acta Pharmacol Sin 35, 1111-1120.
[16] Samtani MN, Farnum M, Lobanov V, Yang E, Raghavan N, Dibernardo A, Narayan V (2012) An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative. J Clin Pharmacol 52, 629-644.
[17] Samtani MN, Raghavan N, Shi Y, Novak G, Farnum M, Lobanov V, Schultz T, Yang E, DiBernardo A, Narayan VA (2013) Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes. Br J Clin Pharmacol 75, 146-161.
[18] Samtani MN, Raghavan N, Novak G, Nandy P, Narayan VA (2014) Disease progression model for Clinical Dementia Rating-Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative. Neuropsychiatr Dis Treat 10, 929-952.
[19] Samtani MN, Xu SX, Russu A, Adedokun OJ, Lu M, Ito K, Corrigan B, Raje S, Brashear HR, Styren S, Hu C (2015) Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab. Alzheimers Dement (N Y) 1, 157-169.
[20] Zhang N, Lv Y, Li H, Chen J, Li Y, Yin F, Li L, Zheng Q (2019) Quantifying placebo responses in clinical evaluation of neuropsychiatric symptoms in Alzheimer's disease. Eur J Clin Pharmacol 75, 497-509.
[21] Kennedy RE, Cutter GR, Fowler ME, Schneider LS (2018) Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis. JAMA Netw Open 1, e184080.
[22] Watanabe M, Nakamura Y, Yoshiyama Y, Kagimura T, Kawaguchi H, Matsuzawa H, Tachibana Y, Nishimura K, Kubota N, Kobayashi M, Saito T, Tamura K, Sato T, Takahashi M, Homma A (2019) Analyses of natural courses of Japanese patients with Alzheimer's disease using placebo data from placebo-controlled, randomized clinical trials: Japanese Study on the Estimation of Clinical course of Alzheimer's disease. Alzheimers Dement (N Y) 5, 398-408.
[23] Schneider LS, Insel PS, Weiner MW (2011) Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurol 68, 58-66.
[24] Henley DB, Dowsett SA, Chen YF, Liu-Seifert H, Grill JD, Doody RS, Aisen P, Raman R, Miller DS, Hake AM, Cummings J (2015) Alzheimer's disease progression by geographical region in a clinical trial setting. Alzheimers Res Ther 7, 43.
[25] Ito K, Corrigan B, Romero K, Anziano R, Neville J, Stephenson D, Lalonde R (2013) Understanding placebo responses in Alzheimer's disease clinical trials from the literature meta-data and CAMD database. J Alzheimers Dis 37, 173-183.
[26] Byon W, Smith MK, Chan P, Tortorici MA, Riley S, Dai H, Dong J, Ruiz-Garcia A, Sweeney K, Cronenberger C (2013) Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacometrics Syst Pharmacol 2, e51.
[27] Kang D, Bae KS, Houk BE, Savic RM, Karlsson MO (2012) Standard Error of Empirical Bayes Estimate in NONMEM(R) VI. Korean J Physiol Pharmacol 16, 97-106.
[28] Cheng Q, Huang J, Xu L, Li Y, Li H, Shen Y, Zheng Q, Li L (2019) Analysis of time-course, dose-effect, and influencing factors of antidepressants in the treatment of acute adult patients with major depression. Int J Neuropsychopharmacol.
[29] Li T, Yang J, Lv Y, Yin F, Xu L, Liu H, Zheng Q, Li L (2019) Quantitative comparison of drug efficacy in treating hot flashes in patients with breast cancer. Breast Cancer Res Treat 173, 511-520.
[30] Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PD (2014) Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. Jama 311, 33-44.
[31] Schneider LS, Kennedy RE, Wang G, Cutter GR (2015) Differences in Alzheimer disease clinical trial outcomes based on age of the participants. Neurology 84, 1121-1127.
[32] Ashford JW, Schmitt FA (2001) Modeling the time-course of Alzheimer dementia. Curr Psychiatry Rep 3, 20-28.
[33] Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, Searcey T, Bierer L, Davis KL (1994) A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 151, 390-396.
[34] Berres M, Kukull WA, Miserez AR, Monsch AU, Monsell SE, Spiegel R (2014) A Novel Study Paradigm for Long-term Prevention Trials in Alzheimer Disease: The Placebo Group Simulation Approach (PGSA): Application to MCI data from the NACC database. J Prev Alzheimers Dis 1, 99-109.
[35] Spiegel R, Berres M, Miserez AR, Monsch AU (2011) For debate: substituting placebo controls in long-term Alzheimer's prevention trials. Alzheimers Res Ther 3, 9.
[36] Cortes-Canteli M, Iadecola C (2020) Alzheimer's Disease and Vascular Aging: JACC Focus Seminar. J Am Coll Cardiol 75, 942-951.
[37] Li F, Nasir M, Olten B, Bloch MH (2019) Meta-Analysis of Placebo Response in Adult Antidepressant Trials. CNS Drugs 33, 971-980.